Stage III Breast Cancer Recruiting Phase 2 Trials for Cediranib (DB04849)

IndicationStatusPhase
DBCOND0031775 (Stage III Breast Cancer)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02498613A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid TumorsTreatment